Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    AID-ICU
Previous Study | Return to List | Next Study

Agents Intervening Against Delirium in Intensive Care Unit (AID-ICU)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03392376
Recruitment Status : Recruiting
First Posted : January 8, 2018
Last Update Posted : October 27, 2020
Sponsor:
Collaborators:
Centre for Research in Intensive Care (CRIC)
Copenhagen Trial Unit, Center for Clinical Intervention Research
Scandinavian Critical Care Trials Group
The Danish Centre of Applied Social Science (VIVE)
Information provided by (Responsible Party):
Zealand University Hospital

Brief Summary:
Delirium is a frequent condition in the Intensive Care Unit (ICU) with no existing evidence-based treatment. The aim of the AID-ICU study is to assess the benefits and harms of haloperidol treatment for the management of ICU acquired delirium.

Condition or disease Intervention/treatment Phase
Delirium Drug: Haloperidol Injection Other: Saline (0,9%) Phase 4

Detailed Description:
Delirium among critically ill patients in the intensive care unit (ICU) is a common condition associated with increased morbidity and mortality. No evidence-based treatment exist of this condition. Haloperidol is the most frequently used agent to treat ICU-related delirium, but according to the available literature there is no firm evidence of efficacy and safety of this intervention. AID-ICU aims to assess the benefits and harms of haloperidol in adult, critically ill patients with delirium in the ICU.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Agents Intervening Against Delirium in Intensive Care Unit (AID-ICU) A Randomized, Blinded, Placebo-controlled Trial
Actual Study Start Date : June 13, 2018
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : June 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Delirium

Arm Intervention/treatment
Experimental: Haloperidol injection

Haloperidol 2,5mg x 3 daily, with additional as needed doses to a maximum of 20mg/daily.

Other name: Serenase

Drug: Haloperidol Injection
ICU patients with diagnosed delirium are treated with 2,5mg haloperidol x 3 daily intravenously with additional as needed doses to a maximum of 20mg/daily.
Other Name: Serenase

Placebo Comparator: Normal Saline
Saline (0,9%)
Other: Saline (0,9%)
ICU patients with diagnosed delirium are treated with 0,5ml isotonic saline x 3 daily and as needed doses to a maximum of 4ml/daily, corresponding to the algorithm in the experimental arm.




Primary Outcome Measures :
  1. Days alive out of the hospital within 90 days post-randomization [ Time Frame: 90 days ]
    Number of days alive and out of hospital


Secondary Outcome Measures :
  1. Number of days alive without delirium or coma in the ICU [ Time Frame: Until ICU discharge, maximum 90 days ]
    Number of days where patients are both alive and free of delirium and coma

  2. Number of patients with one or more serious adverse reactions to haloperidol and the total number of serious adverse reactions to haloperidol compared with placebo [ Time Frame: Measured every day from inclusion until ICU discharge, maximum 90 days ]
    Serious adverse reactions are: Anaphylactic reactions, Agranulocytosis, Pancytopenia, Ventricular arrhythmia, Extrapyramidal symptoms, Tardive dyskinesia, Malignant Neuroleptic Syndrome, Acute hepatic failure

  3. Usage of escape medicine [ Time Frame: Measured every day from inclusion until ICU discharge, maximum 90 days ]
    Number of patients receiving escape medicine and number of days with escape medicine per patients

  4. Number of days alive without mechanical ventilation within 90 days postrandomisation [ Time Frame: Measured every day from inclusion until ICU discharge, maximum 90 days ]
    Number of days where patients are both alive and free of mechanical ventilation

  5. Mortality [ Time Frame: 1 year ]
    Landmark mortality 1 year post-randomisation

  6. Quality of life (five level) [ Time Frame: 1 year ]
    EQ-5D-5L total score 1 year post-randomisation (1-5 of each of the five domains)

  7. Quality of life (overall self assessment) [ Time Frame: 1 year ]
    EQ-Visual Analogue Scale 1 year post-randomisation (0-100)

  8. Cognitive function 1 year after randomisation at selected sites [ Time Frame: 1 year ]
    Repeated Battery for the Assesment of Neuropsychological Status score 1 year post-randomisation at selected sites (40-150)

  9. Executive function 1 year after randomisation at selected sites [ Time Frame: 1 year ]
    Trail Making Test 1 year post-randomisation at selected sites (40-150)

  10. A health economic analysis [ Time Frame: 90 days ]
    The analytic details will be based on the primary results of the trial (cost-benefit or cost-minimisation analyses)

  11. Cognitive function at admission [ Time Frame: At inclusion (within the first week) ]
    Informant Questionnaire on Cognitive Decline in the Elderly at ICU admission at selected sites (40-150)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Acute admission to the ICU AND
  • Age ≥ 18 years AND
  • Diagnosed delirium with validated screening Tool as either CAM-ICU or ICDSC

Exclusion Criteria:

  • Contraindications to haloperidol
  • Habitual treatment with any antipsychotic medication or treatment with antipsychotics in the ICU prior to inclusion
  • Permanently incompetent (e.g. dementia, mental retardation)
  • Delirium assessment non-applicable (coma or language barriers)
  • Withdrawal from active therapy
  • Fertile women (women < 50) with positive urine human chorionic gonadotropin (hCG) or plasma hCG.
  • Consent according to national regulations not obtainable
  • Patients under coercive measures by regulatory authorities
  • Patients with alcohol-induced delirium (Delirium Tremens)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03392376


Contacts
Layout table for location contacts
Contact: Lone Musaeus Poulsen, MD +4547326451 lmp@regionsjaelland.dk
Contact: Nina Christine Andersen-Ranberg, MD +4547326493 ncan@regionsjaelland.dk

Locations
Show Show 18 study locations
Sponsors and Collaborators
Zealand University Hospital
Centre for Research in Intensive Care (CRIC)
Copenhagen Trial Unit, Center for Clinical Intervention Research
Scandinavian Critical Care Trials Group
The Danish Centre of Applied Social Science (VIVE)
Investigators
Layout table for investigator information
Study Chair: OIe Mathiesen, MD, PhD Zealand University Hospital
Study Chair: Anders Perner, MD,PhD Rigshospitalet, Denmark
Study Chair: Jørn Wetterslev, MD, PhD Copenhagen Trial Unit, Center for Clinical Intervention Research
Additional Information:
Study Data/Documents: Statistical Analysis Plan  This link exits the ClinicalTrials.gov site
Identifier: DOI: 10.1111/aas.13661
Published Statistical Analysis Plan for the AID-ICU trial
Study Protocol  This link exits the ClinicalTrials.gov site
Identifier: DOI: 10.1111/aas.13453
Published Study Protocol for the AID-ICU trial

Layout table for additonal information
Responsible Party: Zealand University Hospital
ClinicalTrials.gov Identifier: NCT03392376    
Other Study ID Numbers: REG-169-2017
First Posted: January 8, 2018    Key Record Dates
Last Update Posted: October 27, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Zealand University Hospital:
ICU Delirium
Haloperidol
Additional relevant MeSH terms:
Layout table for MeSH terms
Delirium
Confusion
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Neurocognitive Disorders
Mental Disorders
Haloperidol
Haloperidol decanoate
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anti-Dyskinesia Agents